Highlights of This Issue
Abstract
Highlights of This Issue var callbackToken='505CABF4D8595A7'; var subCode='aacrjnl_sub'; var GAM_sitepage = 'Article_Pages'; var googletag = googletag || {}; googletag.cmd = googletag.cmd || []; (function() { var gads = document.createElement('script'); gads.async = true; gads.type = 'text/javascript'; var useSSL = 'https:' == document.location.protocol; gads.src = (useSSL ? 'https:' : 'http:') + '//www.googletagservices.com/tag/js/gpt.js'; var node = document.getElementsByTagName('script')[0]; node.parentNode.insertBefore(gads, node); })(); googletag.cmd.push(function() { googletag.defineSlot('/2721576/Molecular_Cancer_Therapeutics/FullText_728x90_Top', [728, 90], 'div-gpt-ad-1388416681694-0').addService(googletag.pubads()); googletag.pubads().enableSingleRequest(); googletag.enableServices(); }); Skip to main page content Home OnlineFirst Current Issue Past Issues Subscriptions Alerts Feedback AACR Publications CME AACR Home Search MCT GO Advanced Search Institution: DeepDyve User Name Password Sign In Advertisement googletag.cmd.push(function() { googletag.display('div-gpt-ad-1388416681694-0'); }); Highlights of This Issue Next Section Bispecific HER2-Targeting FynomAb with Superior Antitumor Activity Brack et al. Page 2030 In this study, Brack and colleagues created a series of bispecific HER2-targeting antibodies (FynomAbs) capable of simultaneously targeting two distinct epitopes on HER2, among which COVA208 proves to be the most potent in inhibiting HER2-mediated signaling. Compared with two FDA-approved anti-HER2 antibodies, trastuzumab and pertuzumab, COVA208 showed a different mechanism of action and superior antitumor activity in four different xenograft models. The bispecific FynomAb COVA208 has the potential to enhance the clinical efficacy of HER2-directed therapies, and delineates